Close Menu

NEW YORK – The US Food and Drug Administration has allowed marketing of a rapid lateral flow immunoassay-based test from OraSure Technologies to detect Ebola virus infection, the company announced on Thursday.

The test, which was reviewed under the de novo premarket review pathway, is the first rapid diagnostic for Ebola that the FDA has allowed to be marketed and it was also granted breakthrough device designation by the agency. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.